Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Molecular Docking As a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes Publisher



Arjmand B1 ; Hamidpour SK1 ; Alavimoghadam S1 ; Yavari H1 ; Shahbazbadr A1 ; Tavirani MR2 ; Gilany K3, 4, 5 ; Larijani B6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Reproductive Immunology Research Center, Avicenna Research Institute (ARI), Tehran, Iran
  4. 4. Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Antwerp, Belgium
  5. 5. Breast Cancer Research Center, Motamed Cancer Institute, Tehran, Iran
  6. 6. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Pharmacology Published:2022


Abstract

Cancer stem cells (CSCs) are subpopulation of cells which have been demonstrated in a variety of cancer models and involved in cancer initiation, progression, and development. Indeed, CSCs which seem to form a small percentage of tumor cells, display resembling characteristics to natural stem cells such as self-renewal, survival, differentiation, proliferation, and quiescence. Moreover, they have some characteristics that eventually can demonstrate the heterogeneity of cancer cells and tumor progression. On the other hand, another aspect of CSCs that has been recognized as a central concern facing cancer patients is resistance to mainstays of cancer treatment such as chemotherapy and radiation. Owing to these details and the stated stemness capabilities, these immature progenitors of cancerous cells can constantly persist after different therapies and cause tumor regrowth or metastasis. Further, in both normal development and malignancy, cellular metabolism and stemness are intricately linked and CSCs dominant metabolic phenotype changes across tumor entities, patients, and tumor subclones. Hence, CSCs can be determined as one of the factors that correlate to the failure of common therapeutic approaches in cancer treatment. In this context, researchers are searching out new alternative or complementary therapies such as targeted methods to fight against cancer. Molecular docking is one of the computational modeling methods that has a new promise in cancer cell targeting through drug designing and discovering programs. In a simple definition, molecular docking methods are used to determine the metabolic interaction between two molecules and find the best orientation of a ligand to its molecular target with minimal free energy in the formation of a stable complex. As a comprehensive approach, this computational drug design method can be thought more cost-effective and time-saving compare to other conventional methods in cancer treatment. In addition, increasing productivity and quality in pharmaceutical research can be another advantage of this molecular modeling method. Therefore, in recent years, it can be concluded that molecular docking can be considered as one of the novel strategies at the forefront of the cancer battle via targeting cancer stem cell metabolic processes. Copyright © 2022 Arjmand, Hamidpour, Alavi-Moghadam, Yavari, Shahbazbadr, Tavirani, Gilany and Larijani.
Other Related Docs
9. Metabolomics Analysis of Mesenchymal Stem Cells, International Journal of Molecular and Cellular Medicine (2019)
15. Metabolomics Signatures of Sars-Cov-2 Infection, Advances in Experimental Medicine and Biology (2022)
22. Brown Adipose Tissue and Alzheimer’S Disease, Metabolic Brain Disease (2023)
25. Cancer Stem Cells, Stem Cells in Urology (2020)
26. Advancement of Organoid Technology in Regenerative Medicine, Regenerative Engineering and Translational Medicine (2023)
36. Commercial and Regulatory Challenges in Cancer Nanomedicine, Functionalized Nanomaterials for Cancer Research: Applications in Treatments# Tools and Devices (2024)
43. Chemotherapy: A Double-Edged Sword in Cancer Treatment, Cancer Immunology# Immunotherapy (2022)